Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

2007 ---- ---- Net cash provided by operating activities $91,437 $122,867 Net cash provided by (used in) Investing activities 15,440 (216,176) Net cash (used in)/provided by financing activities (10,070) 221,471 Selected Consolidated Balance Sheet Data December 31, December 31, (in thousands) 2008 2007 ---- ---- Assets Current assets: Cash and cash equivalents $275,839 $179,691 Short-term investments - 404,637 Deferred income taxes 26,785 7,983 Total current assets 356,445 622,773 Intangible assets, net 639,693 122,502 Goodwill 34,787 - Deferred income taxes 91,757 12,312 Total assets 1,147,574 776,066 Liabilities and Stockholders' Equity Total current liabilities $51,086 $28,370 Deferred tax liabilities 181,392 - Long-term debt 250,000 250,000 Total liabilities 486,550 279,503 Total stockholders' equity 661,024 496,563 Total liabilities and stockholders' equity 1,147,574 776,066


'/>"/>
SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution QuantAnalytics(TM) ... management and clinical markets. The software increases the speed ... users to highlight and review results that are of ... to filter results by group or based on a ... need to sift through analytes of no interest. In ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... Plexus Corp. (Nasdaq:,PLXS), today announced it will release its fiscal 2008 ... April 23rd after,the stock market closes. Senior management will host a ... 24th at 8:30 a.m.,Eastern Time., What: ... When: Thursday, April 24th at 8:30 a.m. ...
... from Continuing Operations Driven by ... Continuing Operations of $1.3 Billion ... First Quarter 2008 GAAP EPS from Continuing Operations of $0.35 Compared ... Continuing Operations of $0.42 Compared to $0.36 ...
... Commercial Operating ... ... ; MTAX) today announced that Craig W. Philips, most recently,Vice President ... CTI with direct responsibilities for all Development and,Commercial Operations, effective August ...
Cached Biology Technology:Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T. 2Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 2Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 3Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 4Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 5Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 6Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 7Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 8Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 9Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 10Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 11Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 12Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 13Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 14Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 15Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 16Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 17Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 18Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company 19Veteran Drug Industry Executive to Become President of CTI 2Veteran Drug Industry Executive to Become President of CTI 3Veteran Drug Industry Executive to Become President of CTI 4
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... Researchers in Australia are developing diversionary tactics to ... those responsible for major gut infections, such as cholera, ... to complex sugar receptors displayed on the surface of ... Society for General Microbiology,s meeting at Heriot-Watt University, Edinburgh, ...
... fat removed during liposuction conceal versatile cells that are ... stem cells, or iPS cells, than are the skin ... new study from Stanford,s School of Medicine. "We,ve identified ... co-author of the research, Michael Longaker, MD, who has ...
... Bacteria that generate significant amounts of electricity could be ... remote environments or to convert waste to electricity. Professor ... bacteria with large numbers of tiny projections called pili ... power in fuel cells than bacteria with a smooth ...
Cached Biology News:Designing probiotics that ambush gut pathogens 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 3
... 2-color staining method for labeling DNA breaks ... cells by flow cytometry. The kit contains ... apoptosis in cells including positive and negative ... reaction and rinsing buffers for processing individual ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... the latest entry in the Biomek line. With ... increased robustness, it can meet the needs of ... with either one or two pipetting pods. With ... the standard for flexible laboratory solutions to meet ...
... By incorporating a wide range of ... NX sets a new standard for flexible ... liquid handling including pipetting, dilution, dispensing, ... system thats as powerful and flexible as ...
Biology Products: